🔴 GT Biopharma is trading 5.17% down in pre-market with no clear company-specific catalyst identified

GT Biopharma is trading at $0.29, down 5.17%, after no clear company-specific catalyst was identified for August 25, 2026.

• The latest listed release remains the August 14, 2026 second-quarter update, covering ongoing Phase 1 trials and cash runway.
• No August 25 announcement appears in the press-release archive; the broader market is modestly higher.
• Trading activity and volume data were unavailable.